3.61 USD
-0.01 (-0.28%)
3.44 USD
-0.17 (-4.71%)
Taking everything into account, EVO scores 2 out of 10 in our fundamental rating. EVO was compared to 57 industry peers in the Life Sciences Tools & Services industry. EVO may be in some trouble as it scores bad on both profitability and health. EVO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year EVO has reported negative net income.
- In the past year EVO had a positive cash flow from operations.
- In multiple years EVO reported negative net income over the last 5 years.
- In the past 5 years EVO always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of -8.97%, EVO is in line with its industry, outperforming 45.61% of the companies in the same industry.
- EVO has a Return On Equity (-19.87%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.97% | ||
| ROE | -19.87% | ||
| ROIC | N/A |
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 10.82%, EVO is doing worse than 87.72% of the companies in the same industry.
- In the last couple of years the Gross Margin of EVO has declined.
- The Profit Margin and Operating Margin are not available for EVO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
2. Health
2.1 Basic Checks
- EVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, EVO has more shares outstanding
- Compared to 5 years ago, EVO has more shares outstanding
- The debt/assets ratio for EVO has been reduced compared to a year ago.
2.2 Solvency
- EVO has an Altman-Z score of 0.58. This is a bad value and indicates that EVO is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of 0.58, EVO is not doing good in the industry: 71.93% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.48 indicates that EVO is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.48, EVO is not doing good in the industry: 64.91% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.58 |
ROIC/WACCN/A
WACC7.74%
2.3 Liquidity
- A Current Ratio of 2.12 indicates that EVO has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 2.12, EVO is in line with its industry, outperforming 42.11% of the companies in the same industry.
- A Quick Ratio of 2.03 indicates that EVO has no problem at all paying its short term obligations.
- The Quick ratio of EVO (2.03) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.03 |
3. Growth
3.1 Past
- EVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.17%.
- Looking at the last year, EVO shows a decrease in Revenue. The Revenue has decreased by -2.67% in the last year.
- Measured over the past years, EVO shows a quite strong growth in Revenue. The Revenue has been growing by 12.29% on average per year.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
3.2 Future
- EVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.42% yearly.
- EVO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.78% yearly.
EPS Next Y62.04%
EPS Next 2Y36.34%
EPS Next 3Y28%
EPS Next 5Y18.42%
Revenue Next Year-2.93%
Revenue Next 2Y2.64%
Revenue Next 3Y5.43%
Revenue Next 5Y4.78%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- EVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EVO is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 690.06 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as EVO's earnings are expected to grow with 28.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.34%
EPS Next 3Y28%
5. Dividend
5.1 Amount
- No dividends for EVO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.61
-0.01 (-0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)N/A N/A
Inst Owners50.94%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.28B
Revenue(TTM)756.33M
Net Income(TTM)-158.98M
Analysts78.46
Price Target5.14 (42.38%)
Short Float %0.25%
Short Ratio5.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.59%
Min EPS beat(2)-21.86%
Max EPS beat(2)-3.31%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.97%
Min Revenue beat(2)-9.17%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.99%
Min Revenue beat(4)-9.17%
Max Revenue beat(4)-0.93%
Revenue beat(8)1
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)1.12%
Revenue beat(16)7
Avg Revenue beat(16)2.95%
PT rev (1m)-3.93%
PT rev (3m)-7.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)733.6%
EPS NY rev (1m)0%
EPS NY rev (3m)10.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.39%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)-0.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.46 | ||
| P/FCF | N/A | ||
| P/OCF | 781.68 | ||
| P/B | 1.38 | ||
| P/tB | 2.21 | ||
| EV/EBITDA | 690.06 |
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)0
OCFY0.13%
SpS2.48
BVpS2.62
TBVpS1.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.97% | ||
| ROE | -19.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.82% | ||
| FCFM | N/A |
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 209.82 | ||
| Cap/Depr | 90.72% | ||
| Cap/Sales | 12.19% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 76.3% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.03 | ||
| Altman-Z | 0.58 |
F-Score4
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y62.04%
EPS Next 2Y36.34%
EPS Next 3Y28%
EPS Next 5Y18.42%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
Revenue Next Year-2.93%
Revenue Next 2Y2.64%
Revenue Next 3Y5.43%
Revenue Next 5Y4.78%
EBIT growth 1Y-6.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.73%
EBIT Next 3Y48.36%
EBIT Next 5Y32.9%
FCF growth 1Y52.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y107.69%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%
EVOTEC SE - SPON ADR / EVO FAQ
Can you provide the ChartMill fundamental rating for EVOTEC SE - SPON ADR?
ChartMill assigns a fundamental rating of 2 / 10 to EVO.
Can you provide the valuation status for EVOTEC SE - SPON ADR?
ChartMill assigns a valuation rating of 1 / 10 to EVOTEC SE - SPON ADR (EVO). This can be considered as Overvalued.
How profitable is EVOTEC SE - SPON ADR (EVO) stock?
EVOTEC SE - SPON ADR (EVO) has a profitability rating of 2 / 10.
What is the financial health of EVOTEC SE - SPON ADR (EVO) stock?
The financial health rating of EVOTEC SE - SPON ADR (EVO) is 3 / 10.
What is the earnings growth outlook for EVOTEC SE - SPON ADR?
The Earnings per Share (EPS) of EVOTEC SE - SPON ADR (EVO) is expected to grow by 62.04% in the next year.